Program
Target
Indication
Discovery
IND-Enabling
Phase 1Targeted Protein Degradation
AC0699
ER Degrader
Breast Cancer
Potential best-in-class, broad mutant coverage
AC0682
ER Degrader
Breast Cancer
Potential best-in-class
AC0176
AR Degrader
Prostate Cancer
Potential best-in-class
AC0676
BTK Degrader (WT & C481S)
Hematology Oncology Indications
High selectivity
Discovery
Undisclosed
Multiple Novel E3 Ligases
Undisclosed
First-in-Class
Small Molecule (Precision Oncology)
Discovery
Undisclosed
Lung Cancer
Discovery
Undisclosed
Solid Tumors
